The dermatology company agreed to acquire ZO Skin Health from its shareholders, including the Obagi family and funds managed by Blackstone Tactical Opportunities. Source: Wall Street Journal Markets · Summarized by HeadlinesBriefing Related articlesAlibaba Leaders’ Buying Does Little to Ease Share Sale FalloutAlphabet Loses $692 Billion in Market Value as AI Questions RiseAsian Stocks Set to Extend AI Chip-Fueled Selloff: Markets WrapAsia Tech Shares Swing Wildly as A.I. Jitters PersistAdvantest Shares Decline After Outlook Misses on Tight CapacityMore from Wall Street Journal MarketsBank of France Making Rates Decisions Meeting by Meeting, Says GovGold Steady Ahead of U.S. Inflation DataFailure of Australia’s Largest IPO in Decades Sends Tremors Through AI TradeOil Rises Amid Ongoing Middle East TensionsAsian Currencies Consolidate Ahead of U.S. CPI DataLatest in Public MarketsGold Fields mounts charm offensive to woo Northern Star investors · Financial Times CompaniesMusk Blames Tycoon for Stalling Satellite Internet Access in India · New York Times BusinessMoody’s Says South Africa Is On Right Track For Rating Upgrade · Bloomberg MarketsL&G Is Hedging Its Bond Purchases Against Risk of Selloff · Bloomberg MarketsCanada Aims for India Trade Deal by Year-End, Minister Says · Bloomberg MarketsRelated briefingsMarkets 24-Hour BriefingMarkets 8-Hour BriefingHomePublic MarketsGalderma to Buy ZO Skin Health for $1.5 BillionSectionsHomePublic MarketsPrivate MarketsTech & GamesMobileDeveloperF1SportsOther languagesEnglish简体中文Españolहिन्दीالعربيةFrançaisবাংলাPortuguêsРусский